---
type: input
input_kind: ai-conversation
source_app: claude-code
title: "We are working on this course right now from MIT Data or"
started_at: 2026-06-05T21:08:01
ended_at: 2026-06-05T21:43:04
project: Cowork
status: raw
session_id: 3d957daa-ec99-49ca-b5e0-ba8c31629a7b
tags:
  - input
  - ai-conversation
  - claude-code
---

# We are working on this course right now from MIT Data or

## You

We are working on this course right now from MIT: "Data or Specimens Only Research", it's a required course so that I can access another portal. I want your help answering any questions that come along in the course. Everything about the module and the course is in this file: `20_Progress/Projects/Research/Healthcare/Courses/MIT Intro/Data or Specimens Only Research`. Refer to this file as the source of truth to answer any questions that I will paste you with in this chat. 

I just covered the first module and it's written in the specified document. Answer these questions correctly, only relying on knowledge from that specific file:

```
Quiz
Instructions: Please provide an answer for all questions. Each question is one point. Click on the Submit button to register your answers. After submitting your answers, the correct answer to each question and an explanation will be displayed. Navigational links to the next module will also be provided.

All quiz questions count towards your score. You should answer all questions.

Question 1
Which of the following proposed studies would constitute human subjects research as defined under the federal regulations?


 A researcher conducts a comparison of the comments made in a publicly available blog and the blogger's comments on a similar topic in a weekly magazine.
 A researcher from a school of social work obtains access to students' academic records (including identifiable information) to assess the effect of drug awareness programs on student academic achievement.
 A researcher uses ships' manifest records of people who entered America between 1875 and 1880 to track the restrictions immigration laws imposed on certain ethnic immigrant groups.
 An organization for women academics in engineering asks a federal agency to provide the number of women investigators funded by that agency to include in a report for its membership.
Question 2
Which of the following activities meets the federal definitions of research?


 Collection of elementary school test scores to evaluate the effectiveness of an experimental program to teach reading
 Public Health Department review of records to determine if it should continue a well-child vaccination program
 Evaluations of time cards by factory managers to see if a newly instituted safety program reduces time lost to injury
 Surveys of hospital patients about food prepared in the hospital’s kitchen to improve meal service in the hospital
```

## Claude

**Q1: B** — A researcher from a school of social work obtains access to students' academic records (including identifiable information) to assess the effect of drug awareness programs on student academic achievement.

This meets both definitions. The students are living individuals; the academic records are identifiable private information (school records are explicitly cited in the module); and the study is a systematic investigation designed to contribute to generalizable knowledge about drug awareness programs.

The other three fail on one or both counts:
- The blog/magazine comparison involves publicly available information — not private information, and the focus is on text, not an identifiable individual.
- The ships' manifest study involves deceased individuals (1875–1880), which explicitly falls outside the definition of "living individual."
- The agency headcount request is about aggregate numbers, not about individuals at all.

---

**Q2: A** — Collection of elementary school test scores to evaluate the effectiveness of an experimental program to teach reading.

This is a systematic investigation designed to contribute to generalizable knowledge (whether an experimental reading program works). The other three are operational or administrative reviews — not designed to generate generalizable knowledge:
- The public health vaccination review is explicitly listed in the module as a "public health surveillance activity" that is **not research**.
- The factory time-card evaluation is an internal operational safety review.
- The hospital meal survey is a service improvement activity, not a systematic investigation aimed at generalizable findings.

*Tools used: ToolSearch, mcp__jarvis__vault_read*

## You

Module 2 has been written down in the same file, here are the questions:

```
Question 1
Identify the term that refers to agreements made between researchers and subjects, through the consent process, about if and how researchers will protect information provided by the subjects.


 Ownership
 Confidentiality
 Identifiable
 Privacy
Question 2
A method to protect subject privacy in research would be:


 Closing the study if there are not enough subjects to provide meaningful data
 Requiring parental consent and minor assent for a minor subject to participate in the research
 Including a staged-consent process (asking for consent at the beginning of every study activity)
 Conducting research activities in a private setting
Question 3
Identify the term that refers to the right to control access to ourselves and to our personal information.


 Identifiable
 Confidentiality
 Privacy
 Ownership
Question 4
Which of the following is a measure researchers can use to protect the confidentiality of subject data?


 Approach potential subjects in a private way.
 Keep sensitive and identifiable data in encrypted files on a password-protected hard drive.
 Disclose that interview questions will include sensitive topics (such as income, health status, and sexual behavior).
 Consent subjects in private rooms where no one can overhear.
```

## Claude

**Q1: Confidentiality** — The module defines confidentiality as exactly this: "agreements made between researchers and subjects, through the consent process, about if and how researchers will protect information provided by the subjects."

**Q2: Conducting research activities in a private setting** — The module lists this explicitly under methods to protect subject privacy. The other options relate to consent procedures, not privacy protection.

**Q3: Privacy** — The module defines privacy as "the right to control access to ourselves and our personal information."

**Q4: Keep sensitive and identifiable data in encrypted files on a password-protected hard drive.** — The module lists "methods for safeguarding data (such as encryption or limited access to identifiable data)" as a confidentiality protection measure. The other options (private approach, sensitive topic disclosure, private consent rooms) are privacy measures, not confidentiality measures — confidentiality applies after data is collected and in the researcher's possession.

*Tools used: mcp__jarvis__vault_read*

## You

Module 3 has been pasted in the file, answer these questions correctly: 

```
Question 1
When the primary potential harm is the breach of individually identifiable data, to protect against such disclosures, researchers should:


 Have the files in physical possession at all times.
 Encrypt the data and store it in password protected files on institutionally maintained servers with limited access.
 Substitute codes for identifiers and maintain code lists and data files in separate files in the research laboratory.
 Only report aggregate data in aggregate form.
Question 2
Which of the following statements about individually identifiable research data is correct?


 Institutional policies override state laws with regard to the release of individually identifiable data.
 Researchers may be required to release individually identifiable information outside the research setting.
 Researchers are responsible for ensuring that individually identifiable data is never released outside the research setting.
 Informing subjects about possible mandated releases of identifiable information is up to the researcher’s discretion.
```

## Claude

**Q1: Encrypt the data and store it in password protected files on institutionally maintained servers with limited access.**

The module lists multiple safeguarding methods, and encryption of transmitted and stored data combined with limited access directly matches the scenario where the primary risk is breach of individually identifiable data. The other options are partial measures — keeping files in physical possession, substituting codes (without the encryption layer), or only reporting aggregates — none fully addresses the complete protection the module describes for this specific risk.

**Q2: Researchers may be required to release individually identifiable information outside the research setting.**

The module explicitly states: "researchers may be compelled to release study data in response to legal action," and lists required reporting of child abuse, communicable diseases, intent to harm, and elder abuse as limits to confidentiality. The other statements are wrong because state laws are not overridden by institutional policies, researchers cannot guarantee identifiable data is *never* released, and the module says limits to confidentiality *must* be spelled out in the consent process — it's not discretionary.

*Tools used: mcp__jarvis__vault_read*

## You

Module 4 has been covered, answer these questions: 

```
Question 1
Which of the following research activities with children qualifies for exemption?


 A researcher interviewing fifth graders whose parents recently divorced.
 A researcher using small focus groups to talk to adolescents about the impact of stereotypes.
 A researcher using a socio-metric measure in the classroom to assess conflict resolution.
 A researcher observing children on a playground to identify bullying behaviors.
Question 2
In accordance with federal regulations, which of the following statements best describes when research with children may be exempt?


 The age of the children to be enrolled in the study determines which categories of exempt research may be used.
 The researcher's assessment of the children's cognitive abilities determines which categories of exempt research may be used.
 Only certain exemption categories can be used with research involving children.
 If the level of risk is minimal, research that may be exempt is the same for adults and children.
```

## Claude

**Q1: A researcher observing children on a playground to identify bullying behaviors.**

The module explicitly lists "A researcher observes children on a playground to determine whether children prefer playmates of their own ethnicity" as an exempt Category 2 example. Observation of public behavior where the researcher does not participate qualifies. The other options all fail: interviewing fifth graders (interviews with children are explicitly not exempt under Category 2), focus groups with adolescents (interaction/participation), and a sociometric measure in the classroom (researcher participates in the classroom activity).

**Q2: Only certain exemption categories can be used with research involving children.**

The module is clear: children can only be exempted under specific categories (1, 2 with restrictions, 4, 5, 6, 7, 8), and certain activities like interviews and surveys are explicitly excluded from Category 2 exemption. Age and cognitive ability are not the determining factors — the category of research activity is. The "same as adults if minimal risk" statement is also wrong, since the regulations impose additional restrictions on children beyond just risk level.

*Tools used: mcp__jarvis__vault_read*

## You

Module 5 has been written, answer these questions: 

```
Question 1
Which of the following activities constitutes engagement in research?


 Obtaining informed consent and conducting research interviews.
 Providing potential subjects with written information about a study.
 Informing prospective subjects about the availability of research.
 Obtaining subjects' permission for researchers to contact them.
Question 2
If federally funded research involves collaboration with an organization that is "engaged" in research in a foreign country, the foreign organization can rely on the U.S. institution’s IRB for its review.


 True
 False
```

## Claude

**Q1: Obtaining informed consent and conducting research interviews.**

The module defines engagement as participating in recruitment, conducting the consent process, obtaining consent, intervening with subjects for research purposes, or receiving identifiable private information. All other options are explicitly listed as activities that do *not* constitute engagement: informing prospective subjects about availability, providing written information without obtaining consent, and seeking permission for investigators to contact subjects.

**Q2: False.**

The module states that if a foreign collaborating organization is engaged in research funded by HHS, it must have its own Federalwide Assurance (FWA) filed with OHRP — the same FWA used by U.S. institutions. Simply relying on the U.S. institution's IRB is not sufficient; the foreign organization must independently have assurances of compliance in place.

*Tools used: mcp__jarvis__vault_read*

## You

You got question 2 wrong. We do make mistakes, answer the questions carefully for the next modules. 

Module 6: Biomed Refresher 2 - History and Ethical Principles has been written, answer these questions:

```
Question 1
According to the Belmont Report, implementing the principle of respect for persons involves:


 Providing compensation that is commensurate with time requirements.
 Ensuring that subject selection is fair.
 Making it clear to subjects that they may withdraw from a study.
 Ensuring that risks to subjects are no more than minimal.
Question 2
The Belmont principle of beneficence requires that:


 Risks are managed to no more than minimal.
 The study makes a significant contribution to generalizable knowledge.
 The use of procedures that increase benefits and decrease harms whenever consistent with sound research design.
 Subjects derive individual benefit from study participation.
Question 3
According to the Belmont Report, the moral requirement that there be fair selection of research subjects, expresses the principle of:


 Non-maleficence
 Justice
 Respect for persons
 Beneficence
```

## Claude

**Q1: Making it clear to subjects that they may withdraw from a study.**

The module states that respect for persons means treating individuals as autonomous agents, with the core implementation being the requirement to obtain informed consent — which includes the right to withdraw. Compensation relates to justice (fair treatment), fair subject selection is justice, and minimal risk is beneficence.

**Q2: The use of procedures that increase benefits and decrease harms whenever consistent with sound research design.**

This is stated verbatim in the module as a rule derived from beneficence. The other options are wrong: "no more than minimal risk" is a threshold, not the principle's requirement; significant contribution to knowledge is not required; and individual benefit to subjects is not required by beneficence.

**Q3: Justice.**

The module states directly: "The principle of justice requires us to treat people fairly and design research so that its burdens and benefits are shared equitably," with one of its rules being "the requirement to select subjects equitably." Non-maleficence is not one of the three Belmont principles at all.

*Tools used: mcp__jarvis__vault_read*

## You

Module 7: Regulations and processes was pasted in the document, answer these questions: 

```
Question 1
Hospitals routinely and systematically collect information on various services they provide. For example, they may collect data from the pharmacy to see if drugs are being dispensed accurately, or they may hand out satisfaction questionnaires to assess if patients are happy with the service being provided to them. Which of the following is the best reason to explain why these data collections may not require prior IRB approval?


 All systematic collections of data on humans must be considered human subject research, requiring IRB approval.
 The hospitals are collecting these data with the intent to maintain or better their individual services and facilities programs, with no intent to share or report the results with any other entity.
 If the data are collected in a coded manner, with no actual names attached to them, then the activity is not considered research, and therefore does not require IRB approval.
 Entities as large as hospitals are generally considered exempt from the requirement to submit proposed activities to their local IRBs.
Question 2
Which of the following activities would not constitute human subjects research under the Common Rule?


 A study that requires collecting a portion of a participant’s health information obtained during standard clinical care.
 Research involving the implantation and study of an investigational pacemaker.
 A study using a quality of life questionnaire in which the participants reveal answers about how they perceive their health during receipt of clinical care.
 A study of cancer rates across various states using only public health records.
```

## Claude

**Q1: The hospitals are collecting these data with the intent to maintain or better their individual services and facilities programs, with no intent to share or report the results with any other entity.**

The module explains that "research" requires a systematic investigation "designed to develop or contribute to generalizable knowledge," and notes that institutions interpret "generalizable knowledge" differently — some define it as information shared outside the institution or made publicly accessible. Hospital quality improvement activities aimed purely at internal operations don't meet this threshold because there's no intent to generate or share generalizable knowledge. The other options are wrong: coded data alone doesn't exclude something from being research, hospitals have no size-based exemption, and not all systematic data collection is automatically research.

**Q2: A study of cancer rates across various states using only public health records.**

This does not constitute human subjects research because public health records are not "private information" — by definition, private information is what an individual reasonably expects will not be made public. Public health records are already publicly accessible, so no identifiable private information is obtained. There is also no intervention or interaction with living individuals. The other three options all clearly qualify: collecting health info during clinical care involves identifiable private information (A), implanting an investigational pacemaker is a direct physical intervention (B), and a quality-of-life questionnaire involves interaction with subjects about their health (C).

*Tools used: mcp__jarvis__vault_read*

## You

Module 8: SBR Methodologies in Biomedical Research was pasted in the document, answer these questions:

```
Question 1
A medical researcher is comparing the results of two surgical techniques to correct a skeletal deformity. There are many obvious risks of participating in this treatment trial, and participants are carefully informed about the likelihood of infection, poor treatment outcome, further damage, etc. The research design includes a questionnaire given to patients about their quality of life before and after the surgery. Because this is just a simple paper and pencil questionnaire, it does not add any risks to the overall study design. Is this true or false?


 True
 False
Question 2
Which of the following research scenarios would present no likelihood of harm to the participants?


 An anonymous telephone interview, conducted over a toll-free number, of women who have experienced domestic violence.
 A survey about sexual attitudes, beliefs, and practices, distributed by an HIV/AIDS prevention study to people randomly selected from a commercial mailing list.
 A published report on problematic behavior and poor school performance among children of different ethnic groups in a known city. The results are published in aggregate, so that there is no way to identify children from a specific school or neighborhood.
 None of the above
Question 3
A researcher proposes to conduct a survey about sexual attitudes, beliefs, and practices. The survey will be mailed out by an HIV/AIDS prevention group to people randomly selected from a commercial mailing list. All of the following are potential harms to participants except:


 Alarm or concern about being approached for a study about HIV/AIDS.
 The possible loss of confidentiality if the questionnaires are handled inappropriately.
 That researcher might receive incomplete data from participants who do not complete the survey.
 Others may assume that the person receiving the mailing has HIV/AIDS.
Question 4
Which of the following research scenarios would present no likelihood of harm to the participants?


 An anonymous telephone interview, conducted over a toll-free number, of women who have experienced domestic violence.
 An interview of elementary school children about their preferred literary genres.
 A survey about sexual attitudes, beliefs, and practices, mailed by an HIV/AIDS prevention study to people randomly selected from a commercial mailing list.
 A study on problematic behavior and poor school performance among children of different ethnic groups in a known city.
```

## Claude

**Q1: False.**

The module explicitly warns that "when a study contains both physical and non-physical procedures, comparison of the risks in the two types of activities could result in underestimating non-physical risks." A quality-of-life questionnaire before and after surgery carries psychological risk — the module specifically cites "thinking about current physical limitations (for example, amputations)" as an example of psychological harm. The questionnaire does add risk and cannot simply be dismissed as harmless.

**Q2: None of the above.**

All three scenarios carry potential harm: the domestic violence telephone interview risks psychological harm from recalling traumatic experiences; the HIV/AIDS survey risks social stigma and confidentiality breaches; and the aggregate report on problematic behavior among ethnic groups risks group harm — the module states that "published reports about beliefs, attitudes and behavior...could stigmatize a tribe, ethnicity, geographic area, or other defined group" even when individual data is protected.

**Q3: That the researcher might receive incomplete data from participants who do not complete the survey.**

Incomplete data is a problem for the researcher's study quality, not a harm to participants. The other three are all genuine participant harms: psychological alarm about being contacted by an HIV/AIDS study, loss of confidentiality through mishandling, and social stigma from others assuming the recipient has HIV/AIDS.

**Q4: An interview of elementary school children about their preferred literary genres.**

Asking children about their favorite books involves no sensitive topics, no traumatic recall, no stigmatizing information, and no legal or economic risks. The other three all carry documented harms: domestic violence interviews risk psychological harm from traumatic recall; the HIV/AIDS mailing risks social stigma and confidentiality breaches; and the ethnic group school performance study risks group-level stigmatization.

*Tools used: mcp__jarvis__vault_read*

## You

Module 9: Genetics Research was just pasted in the document, answer these questions correctly: 

```
Question 1
A researcher conducting a study on the incidence of mutations to the MDR-1 gene in breast cancer has preliminary evidence of a link between mutated MDR-1 and early recurrence. The researcher begins a new trial using prospectively collected tissue samples to further examine the link between the genetic abnormality and disease progression. He believes that he may want to re-contact some or all of the tissue donors (subjects) if the research indicates a positive link between MDR-1 mutation and early disease recurrence. What is the best procedure for an investigator planning to re-contact study subjects who provided tumor tissue for the study?


 There is no best course - such re-contact presents too many risks for the subject and thus is always unethical.
 The investigator should disclose the intention to re-contact during the consent process. That is, before acquiring and analyzing the sample for research.
 Subsequent re-contact of subjects from a genetic study in which identifiable data is collected is permissible only if the patient's physician approves.
 The samples and genetic information should be initially coded. The investigator could break the code to contact subjects as he deems necessary.
Question 2
A researcher is investigating the genetic biomarkers of adult subjects with autism. The research study involves a single blood draw (about one teaspoon of blood) and then genetic analysis of the specimen. How should the researcher inform prospective subjects about the potential risks of harm of this genetic research study?


 By noting that most genetic research risks are quite low and the blood sample will be coded and not contain the subject’s name.
 By minimizing the risks and emphasizing the importance of the work to finding the "Cure" for autism.
 By carefully disclosing (without overstating) the possibilities of economic or insurance bias and of social stigma to the subject and potentially to others in the subject’s family.
 By emphasizing the risk of bruising from the blood draw.
```

## Claude

The file is too large to read fully. Let me target just the Module 9 section.

**Q1: The investigator should disclose the intention to re-contact during the consent process. That is, before acquiring and analyzing the sample for research.**

The module is explicit: "If the investigator plans to re-contact subjects, this must be disclosed in the consent document." Re-contact requires that samples be linked to identifiable information via a code, but the decision and disclosure must happen upfront in the consent process — not at the investigator's later discretion. Re-contact is not inherently unethical, physician approval is not the standard, and the investigator cannot simply break a code as they see fit without prior IRB-approved plans.

**Q2: By carefully disclosing (without overstating) the possibilities of economic or insurance bias and of social stigma to the subject and potentially to others in the subject's family.**

The module identifies the key risks in genetics research as: employment and insurability concerns, social stigma within and beyond the family, pre- and post-test anxiety, group-level stigmatization, and risks to family members who didn't participate. These must be disclosed honestly. The other options all fail: coding the sample doesn't eliminate the risks and doesn't constitute adequate disclosure; minimizing risks violates the consent obligation; and emphasizing only the bruising risk from the blood draw is a significant understatement that ignores the actual genetic risks the module identifies.

*Tools used: mcp__jarvis__vault_read*

## You

Module 10: Records-Based Research was just pasted in the document, read only the specified heading to answer these questions:

```
Question 1
A large HMO has teamed up with several other large HMOs to study falls and footwear. The investigator proposes to review 5,000 medical records across 10 institutions of individuals injured during the last three years from a fall, so she has enough power to detect whether there is a greater number of falls among people who wear clogs. Because individuals wear so many different types of shoes, she will need to review a large number of records to find those few individuals who fit this category. From the medical records, she plans to extract the type of shoe the individuals wear. She will not re-identify the individuals and will not contact the individuals. Which of the following is likely to be the level of review determined as appropriate by the IRB?


 Convened IRB review required, because the study involves the use of private information from multiple institutions.
 Expedited review required, as the study presents no greater than minimal risk but involves the use of medical records that contain sensitive information.
 Limited IRB review required, as a condition of exempt research category.
 Exempt from the regulation, as the study presents no greater than minimal risk and does not collect identifying information.
Question 2
An investigator has proposed a multi-site study of PSA (Prostate Specific Antigen) test results among patients with prostate cancer. The research involves only review of medical records at institutions in several states. The investigator will not collect any identifying information on the subjects, only their PSA scores and ages (which will be collected in a range format so as to not have the person’s specific age). The investigator may correctly conclude that:


 All institutions will require review by the full IRB because risks of the research are not minimal.
 There is no need to contact any IRBs because this research is very low risk and would surely be exempt.
 No IRB review is necessary because the data is de-identified.
 IRB review, or similar process, may be required because generally investigators are not able to determine for themselves if their own research is exempt.
Question 3
A director of a smoking cessation service at a university decided to publish a paper on whether quit rates were higher among clients who were offered as an incentive either a Moonbeams Coffee Shop’s latte coupon or a pre-paid telephone card. The director was testing a hypothesis that coffee drinkers were less likely to quit smoking than telephone users. To do this, he proposed using outcome data on smoking cessation collected by the service, which would be extracted from the university’s files and placed in a separate database with no identifying information other than sex, date of birth, zip code of Moonbeams where the coupons were used, and the telephone number of the research subject. Would this research be eligible for exemption?


 Yes. This is not really research and thus there is no need to contact the IRB.
 Yes. These records should be publicly available.
 Yes. No identifiers are being collected and thus there is no need to contact the IRB.
 No. The investigator may be able to identify subjects based on telephone numbers and birth dates, so this should not be considered exempt.
```

## Claude

**Q1: Exempt from the regulation, as the study presents no greater than minimal risk and does not collect identifying information.**

This fits the exemption criteria exactly: the researcher will not record any identifiers, will not contact subjects, and will not re-identify them — she will only extract the type of shoe worn. The module states research is exempt when "information is recorded by the researcher in such a manner that subjects cannot be identified...The researcher also does not contact the subjects and will not re-identify the subjects." The multi-institution scope doesn't change this — it's the nature of the data collected that determines the level of review.

**Q2: IRB review, or similar process, may be required because generally investigators are not able to determine for themselves if their own research is exempt.**

The module is explicit on this point: "OHRP recommends that researchers do not determine on their own if their research qualifies as exempt from the regulations. Rather, the organization should designate an applicable institutional official (or the IRB) to conduct this review." Even if the research seems clearly low-risk, the investigator cannot self-certify exemption.

**Q3: No. The investigator may be able to identify subjects based on telephone numbers and birth dates, so this should not be considered exempt.**

The exemption requires that subjects "cannot be identified directly or through identifiers linked to the subjects." The module's convened review example explicitly demonstrates this principle: a researcher who "does not plan to collect names" but collects a combination of data that "could make it possible to identify the students" does not qualify for exemption. Here, telephone numbers and birth dates are direct or near-direct identifiers — the subjects could readily be re-identified, so the research does not meet the exemption criteria.

*Tools used: mcp__jarvis__vault_read*

## You

Module 11: Populations in Research Requiring Additional Considerations and/or Protections was just pasted in the document. Only read the specified heading to answer these questions:

```
Question 1
A group of elderly men, whose government disability benefits are the sole source of income, is approached to consider an experimental research study for their current colon cancer. The study involves more than minimal risk, but offers substantial financial incentives that are equal to two months of disability benefits. The IRB will be most concerned about the possibility of:


 Inaccuracy of data
 Inadequacy of research design
 Conflict of interest
 Undue influence on the subjects
```

## Claude

**Q1: Undue influence on the subjects.**

The module directly addresses this scenario: "homeless adults may have the ability to understand and process the information about a potential phase I drug study, but might experience undue influence to participate to receive monetary payment or healthcare they could not otherwise afford." The elderly men here are in an analogous situation — their sole income source is government disability benefits, and the financial incentive equals two months of that income. This creates a situation where economic disadvantage compromises the voluntariness element of autonomy, making it difficult for subjects to freely decline. The Common Rule explicitly lists "economically...disadvantaged persons" as vulnerable to undue influence. The other options (data accuracy, research design, conflict of interest) are not what the module identifies as the core concern for this population.

*Tools used: mcp__jarvis__vault_read*

## You

Module 12: HIPAA and Human Subjects Research was just pasted in the document. Only read the specified heading and answer these questions:

```
Question 1
A researcher may use fully de-identified health information without any authorization from individual subjects.


 True
 False
Question 2
A data use agreement is required when a researcher uses a Limited Data Set (LDS). An LDS must have:


 All direct and indirect identifiers removed
 Only contain identifiers if the subject is deceased
 A promise that re-identification is impossible
 All direct identifiers removed
Question 3
If fully deidentified data are used for research, then:


 Authorization requirements are at the discretion of the organization's privacy officer
 No authorization is required, because fully deidentified data are no longer considered PHI
 Authorization requirements are at the discretion of the IRB
 Authorization, or a specific exemption from authorization, is still required
Question 4
HIPAA requires that all covered entities designate:


 A conflict of interests committee
 A signatory / institutional official
 A privacy official
 A non-scientist member
Question 5
Who determines whether an authorization is required or whether the requirement for an authorization may be waived?


 The principal investigator, using his or her best judgment about an assessment of risk and the application of HIPAA regulations
 The organization's IRB, privacy board, or a designated privacy official, depending on the circumstances
 It is up to each research subject to decide whether an authorization is necessary
 The organization funding the research
```

## Claude

**Q1: True.**

The module states directly: "A researcher may use fully de-identified health information without any authorization from individual subjects." De-identified data is no longer considered PHI by definition, so no authorization is required.

**Q2: All direct identifiers removed.**

The module states: "A LDS must have all direct identifiers removed; however, it may still include information that could 'indirectly' identify the subject using statistical methods." This distinguishes it from full de-identification, which requires both direct and indirect identifiers removed. An LDS is a middle ground — direct identifiers out, indirect identifiers may remain.

**Q3: No authorization is required, because fully deidentified data are no longer considered PHI.**

The module is explicit: "De-identified information is no longer considered PHI, because by definition it is no longer individually identifiable." Since it isn't PHI, HIPAA authorization requirements don't apply. It is not discretionary for the privacy officer or IRB.

**Q4: A privacy official.**

Stated directly in the module: "HIPAA requires that all covered entities designate a privacy official to enforce its requirements."

**Q5: The organization's IRB, privacy board, or a designated privacy official, depending on the circumstances.**

The module states: "An organization's Institutional Review Board (IRB) or Privacy Board (and in some organizations a designated privacy official) may determine that a waiver or alteration of the authorization requirement is appropriate." The principal investigator cannot self-determine this, it is not left to the subject, and the funding organization plays no role in this determination.

*Tools used: mcp__jarvis__vault_read*

## You

Module 13: Conflicts of Interest in Human Subjects Research was just pasted in the document. Only read the specified heading to answer these questions:

```
Question 1

Quiz - Case Study

When does an investigator’s significant financial interest (SFI) become a possible financial conflict of interest (FCOI)? 
 When the SFI could directly and significantly affect the design, conduct or reporting of the funded research
 Only if the SFI is over 15 percent of the investigator’s salary from their organization
 Up to 12 months (one year) after the investigator receives payment
 When the SFI is not disclosed
Question 2
The Public Health Service (PHS), U.S. Food and Drug Administration (FDA), and National Science Foundation (NSF) regulations address:


 Individual non-financial COIs
 Institutional financial COIs
 Individual financial COIs
 Institutional non-financial COIs
Question 3

Quiz - Case Study

Dr. Jones works as a cardiologist at a Midwest University Medical Center and earns approximately $15,000 per year from Big Medicines Pharmaceuticals giving talks to other doctors about one of the company’s marketed drugs that is used to treat heart infections. Dr. Jones has a SFI with Big Medicines Pharmaceuticals because he receives non-salary compensation of over $5,000 from the company. Big Medicines has approached Dr. Jones about his organization participating as a site in a clinical trial. Dr. Jones would be the local principal investigator. The research is a large multi-site, randomized, double-blind, placebo-controlled trial to examine the efficacy of an investigational drug to prevent heart attacks with 3,000 subjects total. It is expected that three to four subjects would be enrolled at Dr. Jones’s site. In the following scenario, some existing safeguards against bias are described.
By the time Dr. Jones is approached by Big Medicine, the drug company has already designed the research plan and the study is ongoing.
The research design itself is randomized and double-blinded. This is one way to guard against manipulation of the study results.
Restricting recruitment and thus the contribution of three or four sets of subject data to the study, out of the 3,000 needed to meet research aims, would also guard against significant impact solely by Dr. Jones.
Finally, assuming there are no “subjective measurements” that Dr. Jones would be expected to obtain that would introduce bias (“How does the subject seem to be feeling at this visit?”); his role would be to collect the data and send it to the company for analysis. It is unlikely that the reporting of the results would be impacted by his FCOI.
How could the organization further add protection against bias in this scenario? 
 Require Dr. Jones to return the $5,000 compensation to the company
 Disclose Dr. Jones’ remuneration from the sponsor in the consent document and the consent process
 Refuse to allow the organization’s participation as a site in the research study
 Remove Dr. Jones from the contract negotiation process with the company
Question 4

Quiz - Case Study

Dr. Jones works as a cardiologist at a Midwest University Medical Center and earns approximately $15,000 per year from Big Medicines Pharmaceuticals giving talks to other doctors about one of the company’s marketed drugs that is used to treat heart infections. Dr. Jones has a SFI with Big Medicines Pharmaceuticals because he receives non-salary compensation of over $5,000 from the company. Big Medicines has approached Dr. Jones about his organization participating as a site in a clinical trial. Dr. Jones would be the local principal investigator. The research is a large multi-site, randomized, double-blind, placebo-controlled trial to examine the efficacy of an investigational drug to prevent heart attacks with 3,000 subjects total. It is expected that three to four subjects would be enrolled at Dr. Jones’s site. Who determines if Dr. Jones has a FCOI with this proposed research? 
 Dr. Jones
 Big Medicines Pharmaceuticals
 Dr. Jones’ organization
 Institutional Review Board (IRB)
Question 5
The PHS regulations require:


 Each “investigator” named on a proposal to disclose “significant financial interests” to the Institutional Review Board (IRB).
 Each “investigator” named on a proposal to disclose “significant financial interests” to the FDA for drug studies.
 Each “investigator” named on a proposal to disclose “significant financial interests” to a designated official at the applicant organization.
 Each “investigator” named on a proposal to disclose “significant financial interests” to the federal funding agency.
```

## Claude

Let me find the exact heading name.

**Q1: When the SFI could directly and significantly affect the design, conduct or reporting of the funded research.**

The module defines it precisely: "a SFI may become a FCOI when the SFI could directly and significantly affect the design, conduct or reporting of the funded research." The other thresholds (salary percentage, time after payment, non-disclosure alone) are not how the module defines the SFI-to-FCOI transition.

**Q2: Individual financial COIs.**

Stated directly: "The PHS, U.S. Food and Drug Administration (FDA), and National Science Foundation (NSF) regulations only address individual financial COIs." Institutional and non-financial COIs are governed by organizational policy, not these federal regulations.

**Q3: Disclose Dr. Jones' remuneration from the sponsor in the consent document and the consent process.**

The existing safeguards already address design manipulation (randomized/double-blind), data impact (only 3-4 of 3,000 subjects), and reporting (company handles analysis). The remaining gap is transparency to subjects. The module states "disclosure reduces the appearance of or the potential for bias in the research" — disclosing the FCOI in the consent document addresses the subjects' right to know about potential bias in the research they're enrolling in.

**Q4: Dr. Jones' organization.**

The module states: "An organization's designated review mechanism in compliance with the definitions and procedures in its written policies will determine when a researcher's SFI becomes a FCOI." Neither the investigator, the sponsor, nor the IRB makes this determination — it's the organization's designated official.

**Q5: Each "investigator" named on a proposal to disclose "significant financial interests" to a designated official at the applicant organization.**

Quoted verbatim in the module: "PHS regulation at 42 CFR 50 requires each 'investigator' named on a PHS proposal to disclose 'significant financial interests' to a designated official at the applicant organization." Disclosure goes to the organization, not to the IRB, the FDA, or the funding agency directly.

*Tools used: mcp__jarvis__vault_read, mcp__workspace__bash*


